Abstract Body

Background

In people living with HIV (PLWH), persistent immune activation remains despite virologic suppression with antiretroviral therapy, thereby reducing vaccine effectiveness. Current guidelines recommend strengthened and individualized vaccination strategies, with viral suppression and immune reconstitution as essential prerequisites. The aim of the study is to evaluate whether chronic HIV infection may also impact the effectiveness of the novel messenger RNA (mRNA)-based vaccines.

Methods

20 PLWH, receiving antiretroviral therapy and virologically suppressed, were enrolled, along with a control group of 20 healthy individuals. Peripheral venous blood samples were collected before vaccination (T0) and one month after completion (T1) of the primary vaccination cycle with the mRNA BNT162b2 anti-SARS-CoV-2 vaccine. Anti-Spike antibody titers were measured. T- and B-cell subpopulations were phenotyped by multiparametric flow cytometry from peripheral blood mononuclear cells, and the expression of the immune activation markers CD38 and HLA-DR was assessed in T-cell subpopulations.

Results

Comparison of post-vaccination antibody titers between the two groups revealed that the humoral immune response in PLWH was, on average, one hundred times lower than in healthy participants (p < 0.001). The strength of this response was directly proportional to the absolute number of CD4+ T cells (p = 0.023) and to the CD4+/CD8+ T-cell ratio (p = 0.028) at the time of vaccination, and inversely proportional to the number of CD8+ T cells (p = 0.031). Analysis of lymphocyte subpopulations revealed no significant changes in immune activation marker expression after vaccination in either group (Figure 1). However, in PLWH, a higher baseline and post-vaccination expression of all studied immune activation markers was observed, consistent with the chronic inflammatory state secondary to HIV infection.

Conclusions

Across groups, mRNA vaccination induced a significant antibody response. However, in PLWH humoral responses to BNT162b2 seem attenuated and tied to CD4 counts and CD4/CD8 ratios, which may have predictive value. Across groups, mRNA vaccination may not elicit activation sufficient for durable protection. PLWH, especially with lower CD4+ T-cell counts, might benefit from repeated vaccination and closer immunological monitoring. No clear vaccine-related rise in immune activation emerged, supporting a favorable safety profile.

Table or Figure